TG Therapeutics Pays $7.5M for Phase 1 Azer-cel MS Milestone
TG Therapeutics triggered a Phase 1 clinical milestone for its azer-cel multiple sclerosis program, resulting in a $7.5 million payment to Precision BioSciences—$5.25 million in cash and 201,504 shares purchased at $11.17 each. This milestone underscores TG Therapeutics’ commitment to its autoimmune pipeline and advances its timeline toward commercialization.
1. Clinical Milestone Achievement
TG Therapeutics’ azer-cel therapy for progressive multiple sclerosis reached a Phase 1 clinical milestone, triggering its first significant development payment under the license agreement with Precision BioSciences. This advancement confirms progression in non-oncology indications and validates the ARCUS platform’s potential for autoimmune applications.
2. Payment Structure
The $7.5 million milestone consists of $5.25 million in upfront cash and a $2.25 million equity component, with Precision issuing 201,504 common shares at $11.17 each. This structure aligns cash conservation for TG with equity investment in its partner’s growth.
3. Financial Impact
While the $5.25 million cash outflow will modestly reduce TG Therapeutics’ liquidity, the structured share purchase mitigates immediate cash burden. TG’s existing balance sheet and access to financing are expected to absorb this payment without derailing other development programs.
4. Future Upside from License Agreement
Under the 2024 license deal, TG Therapeutics holds exclusive global rights to develop and commercialize azer-cel in autoimmune and non-oncology indications, with Precision eligible for up to $288 million in additional milestones and royalties. This framework offers TG Therapeutics potential leverage in pricing negotiations and future partnership expansions.